Mera-med.ru

Онкология
- Лечение онкологии
- Меланома
- Лейкоз
- Острый лейкоз
- Хронический лейкоз
- Лейкоз крови
- Рак



















вакцинотерапия меланома

It is possible to offer two explanations of this phenomenon. First, quality of performance циторедуктивных operations therefore the sizes of residual formations{educations} and volume of residual tumoral weight after performance of operative intervention were essentially reduced has improved. The second reason is connected with the advent of the new antineoplastic preparations possessing activity at a cancer яичников. To such preparations concern, in particular, таксаны (паклитаксел and доцетаксел). Подробнее...

The private residence costs{stands} research ICON-3 in which 2039 patients Ic-IV with stages of a cancer яичников have taken part. In control group patients received карбоплатин in doze AUC> 5 or combination САР (500/50/50 mg / m2), in compared group - a combination цисплатина and паклитаксела (75/175 mg / m2). Treatment was carried out{was spent} each 3 weeks in volume of 6 rates. The preliminary data testify that time before progressing and general life expectancy was identical irrespective of used chemotherapy. Sick (57 %) in group карбоплатина and CAP received the majority таксаны as chemotherapy of the second line that explains rather good remote results. Подробнее...